Shares of CombiMatrix Corporation (CBMX) soar today, finishing up over 334% after the New England Journal of Medicine published two studies concluding chromonosomal microarray analysis (CMA) is superior to standard karyotyping for identifying prenatal genetic abnormalities. CBMX currently is the only publicly traded firm offering CMA diagnostics. One caveat, despite today's big run - the shares still are down over 55% from its $20 peak at the beginning of the year.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs